High-sensitivity C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) have been reported to be independent predictors of atherosclerosis.
association was found between high hs-CRP and Lp-PLA2 levels and carotid stenosis (adjusted odds ratio [OR] : 2.39; 95% confidence interval [CI]: 1.13-5.09), but this combination was not associated with carotid plaques (OR: 2.62, 95% CI: 0.93-7.38).
The results suggested that the combination of hs-CRP and Lp-PLA2 were better predictors than either protein alone with regard to carotid atherosclerosis.
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| INTRODUCTION
Carotid atherosclerosis is a primary cause of stroke and disability worldwide.
1,2 Inflammation is an important predictor of carotid atherosclerosis and plays a critical role in the formation and development of plaques and enhancement of the intima media thickness (IMT). 3 Many inflammatory biomarkers, including lipoprotein-associated phospholipase A2 (Lp-PLA2), fibrinogen, serum amyloid A (SAA) and interleukin-6 (IL-6), have been approved by the United
States Food and Drug Administration (FDA) as predictors of ischemic stroke; additionally, high-sensitivity C-reactive protein (hs-CRP) has been associated with carotid atherosclerosis. 4 Hs-CRP is secreted by the liver in response to IL-6 following a microbial trigger or tissue damage. Numerous studies have shown that elevated hs-CRP levels are significantly associated with an increased risk of carotid atherosclerosis. 5, 6 Indeed, adding CRP to the Framingham risk score improved the cardiovascular risk prediction. 7 Nevertheless, a significant association of hs-CRP with atherosclerosis has not been demonstrated in all epidemiological studies. 8, 9 Compared to hs-CRP, Lp-PLA2 has the advantage of being a more specific marker for cardiovascular risk. 7 However, epidemiological studies conducted in different populations have found inconsistent results regarding whether Lp-PLA2 can be used as a predictor of atherosclerosis. 10 This controversy has fuelled the search for more effective prediction methods for cardiovascular disease.
Several prospective studies have demonstrated that the combination of hs-CRP and Lp-PLA2 improves the prediction of the risk of cardiovascular diseases, including coronary artery disease and stroke. 7, 11 However, the association of hs-CRP with Lp-PLA2 for carotid atherosclerosis is less understood. The aim of this study was to evaluate the association of the combination of hs-CRP and Lp-PLA2
with carotid atherosclerosis in participants with 40 years or older, who participated in the Asymptomatic Polyvascular Abnormalities Community (APAC) study. The carotid atherosclerosis risk prediction obtained by measuring hs-CRP and Lp-PLA2 was discussed.
| ME TH ODS

| Study population
The APAC study is a community-based, observational cohort study aimed at investigating the epidemiology of asymptomatic polyvascular abnormalities in Chinese adults. 12, 13 The inclusion criteria of the APAC study are as follows: (a) ≥40 years old; (b) complete basic information available; and (c) no history of stroke, myocardial infarction, coronary heart disease, transient ischemic attack and neurological deficits. 14, 15 Among the 5440 participants in the APAC study, 1982 participants (mean age 60 ± 11.7 years) with available hs-CRP and Lp-PLA2 levels were included in the final analyses ( Figure 1 ). The present study was performed according to the guidelines of the Helsinki Declaration and was approved by the ethics committees of Kailuan General Hospital and Beijing Tiantan Hospital.
Written informed consent was obtained from all participants.
| Assessment of carotid stenosis and carotid plaque
Bilateral carotid duplex sonography (ACUSON X300, Siemens, Germany) was used to evaluate the presence of carotid stenosis and carotid plaques. 1, 12 The investigators were blinded to the clinical and laboratory examination results of the study participants. A carotid plaque was defined as a focal structure either invading >0.5 mm into the arterial lumen, or invading into at least 50% of the surrounding IMT, or with a thickness at least 1.5 mm from the intimae-lumen interface to the media adventitia interface. Carotid stenosis was assessed using established ultrasound criteria as follows 1 : (a) an internal carotid artery peak systolic velocity ≤125 cm/s was defined as <50% stenosis; (b) an internal carotid artery peak systolic velocity 125-230 cm/s and a visible plaque was defined as 50%-69% stenosis and (c) an internal carotid artery peak systolic velocity >230 cm/s or a markedly narrowed lumen was defined as >70% stenosis. The carotid ultrasound examination results were reviewed by two independent reviewers. Discrepancies were resolved by discussion between the experts or a third examination.
| Determination of the CRP and Lp-PLA2 levels
Hs-CRP was measured with a high-sensitivity nephelometry assay (Cias Latex CRP-H, Kanto Chemical Co. Inc., Tokyo, Japan). The hs-CRP concentrations were categorized into two groups as follows 16 :
high level (hs-CRP+, >3 mg/L) and low level (hs-CRP−, <3 mg/L).
The plasma Lp-PLA2 concentration was measured using a highsensitivity, quantitative sandwich enzyme-linked immunosorbent assay (Quantikine ELISA, R&D Systems Inc. Minneapolis, MN, USA) and categorized into two groups as follows: high level (Lp-PLA2+, >200 ng/mL) and low level (Lp-PLA2−, ≤200 ng/mL). 17 All participants were divided into the following four groups: low hs-CPR/low Lp-PLA2 (hs-CRP−/Lp-PLA2−), high hs-CRP/low Lp-PLA2
(hs-CRP+/Lp-PLA2−), low hs-CRP/high Lp-PLA2 (hs-CRP−/Lp-PLA2+) and high hs-CRP/high Lp-PLA2 (hs-CRP+/Lp-PLA2+).
| Covariates
Questionnaires were used to collect information from the partici- and low-density lipoprotein cholesterol (LDL-C). The assessment of covariates was described in a previous study. 
| Statistical analysis
All continuous variables in our study were normally distributed. Continuous variables were presented as the mean with standard deviation and compared using one-way ANOVA. Categorical variables were compared using the chi-square test. Logistic regression was used to evaluate the association between hs-CRP, Lp-PLA2 and car- All statistical tests were two-sided, and the significance level was set as P < 0.05. The statistical analyses were performed using SAS software, version 9.3 (SAS Institute Inc., Cary, NC, USA).
| RESULTS
| Participant characteristics
Of the 5440 participants in the APAC study, 5349 and 2012 partici- 
| DISCUSSION
In this community-based study, the main finding was that the combination of hs-CRP and Lp-PLA2 was associated with the carotid stenosis risk. The results showed an additive effect of hs-CRP combined with Lp-PLA2 on risk prediction, which suggested a clinically relevant role for hs-CRP combined with Lp-PLA2 in carotid atherosclerosis. and atherosclerotic events, such as coronary heart disease and stroke. 7, 20 An elevated Lp-PLA2 level was shown to be significantly associated with carotid artery plaques, but this association became non-significant when Mendelian randomization methods were adopted. 21 Our findings provide evidence that the combination of the hs-CRP and Lp-PLA2 levels is sufficiently stable to predict carotid artery stenosis independent of other atherosclerotic risk factors. The significant association between high hs-CRP and Lp-PLA2 levels and carotid artery stenosis was still present even after the multivariable adjustments, demonstrating that hs-CRP combined with Lp-PLA2 is an independent risk factor for carotid artery stenosis. The elevated Triglycerides (mmol/L) 1.7 ± 1.4 1.6 ± 1.4 1.9 ± 1.6 1.5 ± 1.9 1.5 ± 0. Lp-PLA2 are a better maker of the atherosclerosis risk than a high level of either protein alone. 22 However, we were unable to demonstrate that high levels of both hs-CRP and Lp-PLA2 were associated with carotid plaques, independent of traditional risk factors. 23, 24 The high prevalence of carotid plaques may have led to a decrease in the statistical power.
Our study has several limitations. First, we measured the Lp-PLA2 concentration but not the Lp-PLA2 activity in the 2012 participants, which might be insufficient to evaluate the effect of Lp-PLA2.
Second, the study was performed based on the Chinese participants who were 40 years of age or older, so it may be not generalizable to other races or the young. Finally, a causal inference may not be drawn in this cross-sectional study.
In conclusion, our results indicated that the combination of CRP and Lp-PLA2 was associated with carotid stenosis. Our findings suggested that the combination of the CRP and Lp-PLA2 levels might be a useful measure for vascular risk assessment and could be a potential therapeutic target for carotid atherosclerosis.
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